Gamma delta chimeric antigen receptor T-cell therapy - Kiromic
Alternative Names: Deltacel; Deltacel/KB-GDT; Gamma delta CAR T-cell therapy - Kiromic Biopharma; KB-GDT-01; KB-GDT™Latest Information Update: 25 Jun 2024
At a glance
- Originator Kiromic
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Non-small cell lung cancer
Most Recent Events
- 20 Jun 2024 Efficacy and adverse event data from the phase I DELTACEL-01 trial in Non-small cell lung cancer released by Kiromic Biopharma
- 06 Jun 2024 Efficacy and adverse event data from the phase I DELTACEL-01 trial in Non-small cell lung cancer released by Kiromic Biopharma
- 29 May 2024 Updated efficacy and adverse event data from the phase I DELTACEL-01 trial in Non-small cell lung cancer released by Kiromic Biopharma